Lantern Pharma Inc. · NASDAQ:LTRN
Lantern Pharma — Investor Presentation (August 2025)
45 slides from Lantern Pharma's investor presentation, Aug 12, 2025
Slide 1: Corporate Overview
Corporate Overview August 12th 2025 NASDAQ: LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Lantern's AI platform RADR is transforming cancer drug discovery
Lantern’s AI 12 5 Lead drug programs* Clinical stage lead platform, RADR®, is powered by AI drug candidates* transforming the 100+ $100M cost, pace, and Issued patents & Approximate total capital timeline of cancer pending applications raised since 2019 drug discovery and 2.5 years $2M development A
Slide 4: Lantern is Transforming Drug Discovery Timelines & Costs with AI
Lantern is Transforming Drug Discovery Timelines & Costs with AI AI insights and Lantern can compress the biomarkers can increase timeline of early-stage drug the odds of clinical trial development by 70% and success by 12X* reduce the cost by 80% (*Parker et al., 2021) RADR® can predict and Lantern
Slide 5: Lantern's AI-Driven Business Model has Multiple Routes Towards Success
Lantern’s AI-Driven Business Model has Multiple Routes Towards Success Areas of Focus Successes to Date High-value 1 Rescue & Based on previous clinical data Partnering and observations, LP-300 was Targeted & Licensing Reposition rescued for never smokers with Clinical Trials Opportunities Drug Cand
Slide 6: Lantern's Diverse & Unique AI Driven Pipeline of Drug Programs
Lantern’s Diverse & Unique AI Driven Pipeline of Drug Programs Lantern has 12 disclosed and collaborative lead drug programs including the Phase 2 HarmonicTM trial Lantern Pharma (NASDAQ: LTRN) Orphan Rare Pediatric Fast Lead Program Indication Discovery Preclinical Phase I Phase II Designation Dise
Slide 7: AI-Powered RADR Modules for Oncology
A proprietary integrated experimental biology, oncology-focused, machine-learning-based drug development platform AI-Powered RADR® Modules for Oncology 200+ Billion* 80%+ Prediction Success Drug Discovery and Development Discover mechanism Characterize specialized m1 of action m5 attributes of a mol
Slide 8: Integrating Data, AI, and Science Across the Drug Development Cycle
Integrating Data, AI, and Science Across the Drug Development Cycle Lantern’s comprehensive computational drug discovery platform roadmap predictbbb.ai • Less than 6% of molecules cross the Blood Brain Barrier (BBB) - one of pharmaceutical development's most persistent challenges • PredictBBBTM achi
Slide 9: Lantern Pharma is a Top 10 End-to-End AI Drug Discovery Company
Lantern Pharma is a Top 10 End-to-End AI Drug Discovery Company According to Deep Pharma Intelligence NASDAQ: LTRN 8
Slide 10: Collaborations
Collaborations Strategic collaborations that are providing unique real-world insights and accelerating timelines World-Class Academic and Research Institutions Biopharma Collaborations NASDAQ: LTRN 9
Slide 11: Eleven FDA Designations Demonstrate our Data-driven, AI-enabled Approach
Eleven FDA Designations Demonstrate our Data-driven, AI-enabled Approach to Transform Drug Development & Strengthen Commercial Value Designation Candidate Indication Date LP-184 Glioblastoma Sep. 2024 Fast Track Designation LP-184 Triple Negative Breast Cancer Dec. 2024 LP-184 Pancreatic Cancer Aug.
Slide 12: LP-300 for the Treatment of NSCLC in Never Smokers
LP-300 for the Treatment of Non-Small Cell Lung Cancer (NSCLC) in Never Smokers Lead Indication Relapsed NSCLC for Never Smokers Clinical Status Phase 2 (multiple patients dosed globally) Market Potential* $4+ billion Indication Size* 150,000 + Cases Target/ MOA Tyrosine Kinases & Cell Redox Enzymes
Slide 13: Disease Overview – NSCLC in Never Smokers – LP-300
Disease Overview – NSCLC in Never Smokers – LP-300 NSCLC in never smokers is one of the largest unaddressed cancer populations Global Annual Market Potential: $ 4+ Billion NSCLC in Never Smokers is a Different Disease Lung Cancer in never smokers has higher percentage of genetic mutations in Tyrosin
Slide 14: LP-300 Nearly Doubled Survival Outcomes for Never Smoker Subgroups
LP-300 Nearly Doubled Survival Outcomes for Never Smoker Subgroups with NSCLC in Previous Clinical Trial* *Subpopulations receiving paclitaxel/cisplatin + 125% increase in median 2 year survival + 91% increase in median overall survival 80% 30 control 72% control LP-300 + Chemo LP-300 + Chemo 25.2 M
Slide 15: Mechanism of Action – LP-300
Mechanism of Action – LP-300 LP-300’s multimodal MoA resensitizes NSCLC to chemo in the never smoker population 1. LP-300 Directly Engages with TKI Receptors via Cysteine Modification LP-300 Modulates Cellular Redox in Key 2. Signaling Pathways in NSCLC A. B. C. D. A-B. LP-300 adduct at Cys1235 Cys1
Slide 16: Clinical Trial – The Harmonic Phase 2 Trial for LP-300
Clinical Trial – The HarmonicTM Phase 2 Trial for LP-300 Accelerating recruitment efforts for a growing indication with limited treatment options NCT05456256 Phase 2 Trial Design Multi-national Phase 2 Trial with 8 sites in the US, 5 sites in Japan, and 5 sites in Taiwan 60 Patients will receive LP-3
Slide 17: Safety Lead-in for Phase 2 Clinical Trial, Summary
Safety Lead-in for Phase 2 Clinical Trial, Summary No Dose Limiting Toxicities or Serious Adverse Events were observed & Lantern received approval from the DSMB (Data & Safety Monitoring Board) to proceed to next phase of the trial ● Overall, LP-300 in combination with the chemo doublet has been wel
Slide 18: Initial Cohort / Lead-in Phase – Summary Results & Key Takeaways
Initial Cohort / Lead-in Phase – Summary Results & Key Takeaways LP-300+ KEY PATIENT CHARACTERISTICS Tumor Response Carboplatin + Pemetrexed ü Patients who are never smokers with lung Partial Response 3/7 (43%) cancer and histopathological evidence of Stable Disease 3/7 (43%) stage III or IV primary
Slide 19: 6 Out of 7 Patients Showed Clinical Benefit in Initial Lead-in Cohort
6 Out of 7 Patients Showed Clinical Benefit in Initial Lead-in Cohort Initial patient responses in the HarmonicTM trial include an 86% disease control rate in the cohort of lead-in patients and a 43% objective response rate (ORR) including one patient maintaining a 50+% reduction in tumor size over
Slide 20: Initial Cohort for Phase 2 – Prior Treatments & Response
Initial Cohort for Phase 2 – Prior Cancer Treatments / History & Response 107-002 107-003 110-001 103-001 110-002 110-003 110-004 Osimertinib Carboplatin Radiotherapy Osimertinib Osimertinib Selpercatinib Osimertinib Keytruda Alimta Radiotherapy Osimertinib Radiotherapy Radiotherapy Osimertinib Selp
Slide 21: Initiated East Asia: Boosting Patient Enrollment in Never Smokers
Initiated East Asia: Boosting Patient Enrollment in Countries with High Incidences of NSCLC in Never Smokers Highlights of all lung cancer • Study expansion to Taiwan and Japan with 5 sites in patients in East Asia are each country never smokers* • First patients enrolled in Japan and Taiwan * Appro
Slide 22: LP-184 for the Treatment of Advanced Solid Tumors
LP-184 for the Treatment of Advanced Solid Tumors DDR deficient solid tumors including Pancreatic cancer, Lead Indications Bladder cancer, and TNBC Phase 1 (multiple cohorts dosed with no dose-limiting toxicity Clinical Status observed) Market Potential* $10+ Billion Indication Size* 170,000 + Cases
Slide 23: Disease Overview – Advanced Solid Tumors with DDR Deficiencies
Disease Overview – Advanced Solid Tumors with DDR Deficiencies LP-184 has Blockbuster Potential Across Multiple Cancers as a Single Agent or in Combination Therapy Annual US Market Potential: $10+ Billion (DDR Deficient Solid Tumors) Advanced Solid Tumors 1 in 4 people have solid • Advanced solid tu
Slide 24: LP-184's MoA was Predicted by RADR and Validated in Multiple Lab Studies
LP-184’s MoA was Predicted by RADR® and Validated in Multiple Lab Studies In silico In vitro Using RADR®, PTGR1 was Identified as a Validated using Biomarker that Predicts LP-184 Response CRISPR Experiments A. B. C. Pancreatic Cancer Cell Viability 1.0 Pancreatic Cancer Cell Viability 1.0 0.8 0.8 0.
Slide 25: LP-184 Treatment Results in Complete Regression in Multiple PDX Models
LP-184 Treatment Results in Complete Regression in Multiple DDR Deficient PDX Models Pancreatic Cancer Triple Negative Breast Cancer (TNBC) In-vitro PDX pancreatic mouse models treated with LP-184 - CTG-1522 and Across 10 TNBC PDX mouse models (All 10 TNBC PDX models were HR CTG-1643 models showed a
Slide 26: Clinical Trial – LP-184 Phase 1 Basket Trial
Clinical Trial – LP-184 Phase 1 Basket Trial Launched Phase 1 basket trial for a blockbuster molecule with a market potential of $10+ billion in annual sales First-In-Human Trial for LP-184 $10+ Bn Clinicaltrials.gov (NCT05933265) Phase 1 Trial Highlights LP-184 Phase 1a Trial Design • Trial launche
Slide 27: Planned Clinical Trials – LP-184 Phase 1b/2 Trials
Planned Clinical Trials – LP-184 Phase 1b/2 Trials informed by RADRⓇ AI Insights TNBC and NSCLC with KEAP1 and/or STK11 mutations and low PD-L1 expression Phase 1b/2 Monotherapy & ~60 • Monotherapy Trial: Open-label study to determine the optimal dose and evaluate the preliminary clinical activity o
Slide 28: LP-184 + Olaparib Combination Achieves 3-14x Greater Tumor Regression
LP-184 + Olaparib Combination Achieves 3-14x Greater Tumor Regression Compared To Olaparib Alone In TNBC PDX Models Tumor regression is achieved using 5x lower doses of LP-184 in combination as compared to doses used as monotherapy Vehicle LP-184 LP-184 LP-184 Olaparib Olaparib LP-184 LP-184 LP-184
Slide 29: LP-184 + Anti-PD1 Combination Inhibits Tumor Growth in TNBC Model
LP-184 + Anti-PD1 Combination Significantly Inhibits Tumor Growth And Delays Progression In T11 Mouse TNBC Model T11 mouse TNBC tumors treated with LP-184 and anti-PD1 antibody LP-184 Demonstrates Anti-Tumor Efficacy in Mouse TNBC Models and Potential to Sensitize Tumors Non-Responsive to Anti-PD1 T
Slide 30: LP-284 for the Treatment of B-cell Non-Hodgkin's Lymphomas
LP-284 for the Treatment of B-cell Non-Hodgkin’s Lymphomas (NHL) Mantle Cell, Double Hit Lymphomas, DDR Deficient Lead Indications Non-Hodgkin’s Lymphomas Phase 1 (multiple patients dosed with no dose-limited Clinical Status toxicity observed) Market Potential* $3.75 - 4 Billion Indication Size* 375
Slide 31: Disease Overview – B-cell Non-Hodgkin's Lymphomas
Disease Overview – B-cell Non-Hodgkin’s Lymphomas Superior responses to LP-284 are observed preclinically Annual Global Market Potential: $ 4 Billion (NHL) B-cell Non-Hodgkin’s Lymphomas LP-284 treatment on NHL Cell lines • NHL is a cancer of the lymphatic system and occurs when normal B-cells, T-ce
Slide 32: Superior Responses to LP-284 Observed Preclinically in Several NHLs
Superior Responses to LP-284 are Observed Preclinically in Several NHLs Including those Resistant to SOC Agents MCL tumor volumes drastically reduced compared Tumors resistant to Ibrutinib and Bortezomib has to FDA approved agents in mice models significantly reduced volume A. Vehicle B. LP-284 (2 m
Slide 33: Clinical Trial – LP-284 Phase 1 Trial
Clinical Trial – LP-284 Phase 1 Trial Ph. 1 trial launched in Q4 2023 for recurrent NHLs with scarce therapeutic options First-In-Human Trial for LP-284 Recent Highlights Q4 Launched • Trial launched and multiple sites activated in the US 2023 Phase 1 trial Program Highlights • LP-284 has nanomolar
Slide 34: LP-284 Highly Synergistic with Rituximab in HGBL Xenograft Models
LP-284 was Highly Synergistic when Used in Combination with Rituximab in HGBL Xenograft Models High Grade B-cell Lymphoma (HGBL) Tumor Volumes in Mice LP-284 – in combination with rituximab HGBL have universally poor prognosis after chemotherapy, such as EPOCH, Hyper CVAD, and CODOX-M/IVAC - all are
Slide 35: Successful Generation and Characterization of Potent Cryptophycin-Loaded ADCs
Successful Generation and Characterization of Potent Cryptophycin-Loaded ADCs A Cryptophycin attached to trastuzumab • Effective ADC Development: Successfully generated Cp-loaded ADCs using native and engineered cysteines in Trastuzumab and THIOMAB variants, leading to highly potent ADC constructs •
Slide 36: Preclinical Proof-of-concept of a Novel Cryptophycin-based ADC
Advanced the Development, Synthesis, and Preclinical Proof- of-concept of a Novel, Highly Potent, Cryptophycin-based ADC Key Highlights • Cryptophycin ADCs showed sub-nanomolar potency across cell lines with medium to high HER2 levels (A,B,C), achieving over 80% cell killing in most cases • The cryp
Slide 37: Starlight has Blockbuster Potential for 500,000+ Patients
Born from Billions of Datapoints & AI, Starlight has Blockbuster Potential to Provide New Treatment Options for 500,000+ Patients There are over 120 types of central 5 Year Survival Rates of CNS nervous system (CNS) and brain And Brain Cancers Remain cancers and a majority have no Low Despite Advanc
Slide 38: Origination of Starlight: RADR Predictions Powered by AI
Origination of Starlight: RADR® Predictions Powered by AI Leading AI Technology, RADR®, Helped Identify • STAR-001 crosses the blood brain barrier • PTGR1 levels correlate with response to STAR-001 • GBM has higher levels of PTGR1 relative to normal brain • STAR-001 anti-cancer activity independent
Slide 39: STAR-001 is Positioned to Expand over Multiple CNS Indications
STAR-001 is Positioned to Expand over Multiple CNS Indications • Tumors with high PTGR1 expression • Tumors with DDR pathway deficiency, synthetic lethality in cancers with deficiencies in NER or homologous repair (~25% of all solid cancers) • PTEN mutant cancers (e.g. endometrial cancer, prostate c
Slide 40: Combination of Spironolactone and LP-184 Enhances Anti-tumor Efficacy in GBM
Combination of Spironolactone and LP-184 Enhances Anti-tumor Efficacy in Glioblastoma Models Treatment of GBM cells with Spironolactone 24h before LP-184 led to…. 3x increase in damage response Depletion of ERCC3 protein by up 1 3-6x increase in LP-184 sensitivity 2 (γH2AX DNA) to LP-184 3 to 95% SP
Slide 41: IP Portfolio
IP Portfolio Intellectual property portfolio builds expanding protections with additional barriers to competition 100 Pending Applications 5 Families 11 Families 2 Families + Issued Patents & Drug Sensitivity & Response Signatures using Biomarkers Methods of Use Composition of Matter RADR LP-300 LP-
Slide 42: Financial Highlights And Cap Table
Financial Highlights And Cap Table • Approx. $15.9 M of cash, cash equivalents and marketable securities as of June 30, 2025 • Committed to creating enduring growth and value for LTRN shareholders LANTERN PHARMA INC. (LTRN) Exchange Nasdaq 52 Week Per Share Price Range (through 8/04/25) $2.56 - $6.1
Slide 43: Leadership & Board of Directors
Leadership & Board of Directors Leadership PANNA SHARMA DAVID MARGRAVE KISHOR BHATIA, Ph.D. Chief Executive Officer & President Chief Financial Officer Chief Scientific Officer PRIOR: President & CEO, Cancer Genetics (CGIX); PRIOR: 20+ years of oncology focused PRIOR: 40+ years experience in cancer CEO
Slide 44: 2025 Investment Highlights
2025 Investment Highlights Recent Milestones Upcoming Milestones & objectives Preliminary patient data showing an 86% clinical benefit rate in Complete Phase 1a clinical trial for LP-184; pursue Phase the initial safety lead-in cohort of the HarmonicTM Phase 2 Trial 1b/2 and investigator led trials
Slide 45: IR Contact
IR Contact: IR@lanternpharma.com 1-972-277-1136 NASDAQ: LTRN www.lanternpharma.com CONNECT WITH US @LanternPharma linkedin.com/company/lanternpharma